|
1
|
Sargent M, Boeck S, Heinemann V, Jauch KW,
Seufferlein T and Bruns CJ: Surgical treatment concepts for
patients with pancreatic cancer in Germany - results from a
national survey conducted among members of the ‘Chirurgische
Arbeitsgemeinschaft Onkologie’ (CAO) and the ‘Arbeitsgemeinschaft
Internistische Onkologie’ (AIO) of the Germany Cancer Society
(DKG). Langenbecks Arch Surg. 396:223–229. 2011.PubMed/NCBI
|
|
2
|
Hackert T, Büchler MW and Werner J:
Surgical options in the management of pancreatic cancer. Minerva
Chir. 64:465–476. 2009.PubMed/NCBI
|
|
3
|
Siegel R, Desantis C, Virgo K, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levi F, Lucchini F, Negri E and La Vecchia
C: Pancreatic cancer mortality in Europe: the leveling of an
epidemic. Pancreas. 27:139–142. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Waldmann TA: Immunotherapy: past, present
and future. Nat Med. 9:269–277. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dranoff G: Coordinated tumor immunity. J
Clin Invest. 111:1116–1118. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Groh V, Rhinehart R, Secrist H, Bauer S,
Grabstein KH and Spies T: Broad tumor-associated expression and
recognition by tumor-derived gamma delta T cells of MICB and MICB.
Proc Natl Acad Sci USA. 96:6879–6884. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
González S, Groh V and Spies T:
Immunobiology of human NKG2D and its ligands. Curr Top Microbiol
Immunol. 298:121–138. 2006.
|
|
9
|
Wu JD, Higgins LM, Steinle A, Cosman D,
Haugk K and Plymate SR: Prevalent expression of the
immunostimulatory MHC class I chain-related molecule is
counteracted by shedding in prostate cancer. J Clin Invest.
114:560–568. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohashi M, Yoshida K, Kushida M, et al:
Adenovirus-mediated interferon gene transfer induces regional
direct cytotoxicity and possible systemic immunity against
pancreatic cancer. Br J Cancer. 93:441–449. 2005. View Article : Google Scholar
|
|
11
|
Märten A, von Lilienfeld-Toal M, Büchler
MW and Schmidt J: Soluble MIC is elevated in the serum of patients
with pancreatic carcinoma diminishing gammadelta T cell
cytotoxicity. Int J Cancer. 119:2359–2365. 2006.PubMed/NCBI
|
|
12
|
Diefenbach A, Jensen ER, Jamieson AM and
Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate
tumour immunity. Nature. 413:165–171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Groh V, Wu J, Yee C and Spies T:
Tumour-derived soluble MIC ligands impair expression of NKG2D and
T-cell activation. Nature. 419:734–738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salih HR, Goehlsdorf D and Steinle A:
Release of MICB molecules by tumor cells: mechanism and soluble
MICB in sera of cancer patients. Hum Immunol. 67:188–195. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boutet P, Agüera-González S, Atkinson S,
et al: Cutting edge: the metalloproteinase
ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding
of the MHC class I-related chain B protein. J Immunol. 182:49–53.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar
|
|
17
|
Plate JM, Plate AE, Shott S, Bograd S and
Harris JE: Effect of gemcitabine on immune cells in subjects with
adenocarcinoma of the pancreas. Cancer Immunol Immunother.
54:915–925. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li K, Mandai M, Hamanishi J, et al:
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in
ovarian cancer: high expression of ULBP2 is an indicator of poor
prognosis. Cancer Immunol Immunother. 58:641–652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schütz A, Härtig W, Wobus M, Grosche J,
Wittekind Ch and Aust G: Expression of ADAM15 in lung carcinomas.
Virchows Arch. 446:421–429. 2005.
|
|
20
|
Chen X, Liao J, Lu Y, Duan X and Sun W:
Activation of the PI3K/Akt pathway mediates bone morphogenetic
protein 2-induced invasion of pancreatic cancer cells PANC-1.
Pathol Oncol Res. 17:257–261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Holdenrieder S, Stieber P, Peterfi A,
Nagel D, Steinle A and Salih HR: Soluble MICB in malignant
diseases: analysis of diagnostic significance and correlation with
soluble MICA. Cancer Immunol Immunother. 55:1584–1589. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaiser BK, Yim D, Chow IT, et al:
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D
ligands. Nature. 447:482–486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Najy AJ, Day KC and Day ML: The ectodomain
shedding of E-cadherin by ADAM15 supports ErbB receptor activation.
J Biol Chem. 283:18393–18401. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lucas N, Najy AJ and Day ML: The
therapeutic potential of ADAM15. Curr Pharm Des. 15:2311–2318.
2009. View Article : Google Scholar
|
|
25
|
Heinemann V, Boeck S, Hinke A, Labianca R
and Louvet C: Meta-analysis of randomized trials: evaluation of
benefit from gemcitabine-based combination chemotherapy applied in
advanced pancreatic cancer. BMC Cancer. 8:822008. View Article : Google Scholar
|
|
26
|
Abou-Alfa GK, Letourneau R, Harker G, et
al: Randomized phase III study of exatecan and gemcitabine compared
with gemcitabine alone in untreated advanced pancreatic cancer. J
Clin Oncol. 24:4441–4447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yanagimoto H, Shiomi H, Satoi S, et al: A
phase II study of personalized peptide vaccination combined with
gemcitabine for non-resectable pancreatic cancer patients. Oncol
Rep. 24:795–801. 2010.PubMed/NCBI
|
|
28
|
Koido S, Homma S, Takahara A, et al:
Current immunotherapeutic approaches in pancreatic cancer. Clin Dev
Immunol. 2011:2675392011. View Article : Google Scholar : PubMed/NCBI
|
